ストックスクリーナーアプリを入手
0.8244
5.26%
0.0412
前日終値:
$0.7832
開ける：
$0.7883
24時間の取引高:
975.40K
Relative Volume:
0.71
時価総額：
$48.47M
収益：
-
当期純損益:
$-123.46M
株価収益率:
-0.3183
EPS:
-2.59
ネットキャッシュフロー:
$-104.11M
1週間 パフォーマンス:
+0.07%
1か月 パフォーマンス:
+19.86%
6か月 パフォーマンス:
+92.48%
1年 パフォーマンス:
-42.35%
1日の値動き範囲:
$0.7801
$0.8568
1週間の範囲:
$0.7501
$0.8568
52週間の値動き範囲:
$0.2601
$1.49
Bioatla Inc Stock (BCAB) Company Profile
BCAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.8244 | 46.05M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-13 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-05-05 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-06-28 | 開始されました | ROTH Capital | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-01-11 | 開始されました | BTIG Research | Buy |
| 2021-01-11 | 開始されました | Credit Suisse | Outperform |
| 2021-01-11 | 開始されました | JP Morgan | Overweight |
| 2021-01-11 | 開始されました | Jefferies | Buy |
すべてを表示
Bioatla Inc (BCAB) 最新ニュース
What drives BioAtla Inc stock priceIndustrial Stocks Review & Exceptional Capital Trading - earlytimes.in
Taking on analysts’ expectations and winning: BioAtla Inc (BCAB) - setenews.com
Is BioAtla Inc. stock positioned well for digital economyTrade Risk Report & Safe Entry Trade Signal Reports - Newser
Will BioAtla Inc. stock continue dividend increasesJuly 2025 Levels & Stepwise Entry and Exit Trade Signals - Newser
Why BioAtla Inc. stock is considered a top pickDollar Strength & High Return Trade Opportunity Guides - Newser
Biotech Momentum Builds In After-Hours Trading As BioAtla, Entero, And Sonnet Climb - Nasdaq
Can BioAtla Inc. stock rebound after recent weaknessMarket Rally & Low Risk Growth Stock Ideas - moha.gov.vn
BioAtla, Inc. (BCAB) -11.3% in Intraday Trading: What’s Driving the Move? - Stocks Telegraph
BioAtla Inc. (BCAB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
The growth track for BioAtla Inc (BCAB) has changed recently - setenews.com
[PRE 14A] BioAtla, Inc. Preliminary Proxy Statement - Stock Titan
BioAtla Reports Q3 2025 Financial Results and Progress - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Form 424B5 BioAtla, Inc. - StreetInsider
[424B5] BioAtla, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
BioAtla Secures $7.5 Million Pre-Paid Advance - TipRanks
[8-K] BioAtla, Inc. Reports Material Event | BCAB SEC FilingForm 8-K - Stock Titan
BioAtla’s New Funding: A Double-Edged Sword for Shareholders - Ad-hoc-news.de
BioAtla Agrees to $22.5 Million in Financing Agreements - MarketScreener
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - Investing News Network
BioAtla, Inc. Secures $7.5 Million Financing to Support Operations During Strategic Partnership Negotiations - Quiver Quantitative
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - GlobeNewswire Inc.
Is BioAtla Inc (BCAB) Good For Your Portfolio? - fostersleader.com
Regression analysis insights on BioAtla Inc. performanceWeekly Trend Summary & AI Enhanced Market Trend Forecasts - newser.com
What catalysts could drive BioAtla Inc. stock higherProfit Target & Fast Gain Swing Trade Alerts - newser.com
Measuring BioAtla Inc.’s beta against major indicesTrade Analysis Report & Community Consensus Trade Alerts - newser.com
Ewing Sarcoma Market Research Report 2025-2035: Salarius, Eli Lilly, Pfizer, and BioAtla Lead by Driving Innovations in the Development of Novel Targeted Therapies - Yahoo Finance
BioAtla Inc. stock outlook for YEAR2025 Breakouts & Breakdowns & Safe Capital Allocation Plans - newser.com
Bioatla Shares Surge on Strong Clinical and Financial Results - Ad-hoc-news.de
Sentiment analysis tools applied to BioAtla Inc.Take Profit & Verified Momentum Watchlists - newser.com
What moving averages say about BioAtla Inc.Portfolio Return Summary & Accurate Entry/Exit Alerts - newser.com
BioAtla Inc (BCAB) can make a big difference with a little luck - Setenews
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch - MSN
Analyzing BioAtla Inc. with multi timeframe chartsMarket Sentiment Report & High Accuracy Swing Entry Alerts - newser.com
Analyzing BioAtla Inc. with risk reward ratio chartsTrade Performance Summary & Weekly Watchlist of Top Performers - newser.com
BioAtla, Inc.Common Stock (Nasdaq:BCAB) Stock Quote - Markets Financial Content
What to do if you’re stuck in BioAtla Inc.Sell Signal & Reliable Price Action Trade Plans - newser.com
Chart overlay techniques for tracking BioAtla Inc.July 2025 Sentiment & Technical Confirmation Alerts - newser.com
Is BioAtla Inc. a candidate for recovery playGap Down & AI Powered Trade Plan Recommendations - newser.com
BioAtla Tightens Belt But Analysts Remain Upbeat - Finimize
Bioatla Inc (BCAB) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):